RVL Pharmaceuticals plc
rvlpharma.comNo Longer Reporting
The company has not filed an annual or quarterly report since its Q2 FY2023 10-Q, filed Aug 14, 2023. Its latest SEC filing is a 8-K from Feb 13, 2024.
10-Q for Q2 FY2023, filed Aug 14, 2023
The sections below describe the company as of the FY2022 annual report.
What Did They Do?
Sells Upneeq, a prescription eye drop for adults with drooping eyelids, to eye-care and medical-aesthetics practices and patients through its pharmacy.
10-K for FY2022, filed Mar 20, 2023We are a specialty pharmaceutical company focused on the development and commercialization of products that target markets with underserved…View ↗
Our healthcare provider customers include optometrists, ophthalmologists, oculoplastic surgeons, facial plastic surgeons, dermatologists…View ↗
Broaden Distribution Channels for Upneeq. Following FDA approval in July 2020, we launched Upneeq in eye care specialties and made the…View ↗
We are focused on growing Upneeq with eye care and medical aesthetic professionals and providing a convenient prescription experience for…View ↗
How Did They Make Money?
Patients and practices buy Upneeq by purchase order, usually paying in advance; invoices sent after delivery are typically due within 30 days. RVL also receives license milestone payments when achieved and royalties on sales in Santen's licensed territories.
10-K for FY2022, filed Mar 20, 2023The Company’s performance obligations are to provide its pharmaceutical products based upon purchase orders from customers. The performance…View ↗
On July 28, 2020, RVL Pharmaceuticals entered into a License Agreement with Santen Pharmaceutical Co. Ltd (“Santen”), granting Santen…View ↗
On March 29, 2022, RVL Pharmaceuticals entered into the First Amendment to License Agreement (the “Amendment”) with Santen, amending the…View ↗
$49.7M
-
10-K for FY2022, filed Mar 20, 2023
$49.7M ↗
Who Were Their Customers?
Eye-care and medical-aesthetics practices buy Upneeq directly, while patients can fill prescriptions through RVL Pharmacy. Telemedicine providers prescribe and ship it to patients.
10-K for FY2022, filed Mar 20, 2023Our healthcare provider customers include optometrists, ophthalmologists, oculoplastic surgeons, facial plastic surgeons, dermatologists…View ↗
Broaden Distribution Channels for Upneeq. Following FDA approval in July 2020, we launched Upneeq in eye care specialties and made the…View ↗
In 2022 we started supplying Upneeq to certain telemedicine providers with established channels to diagnose patients online and prescribe…View ↗
We are focused on growing Upneeq with eye care and medical aesthetic professionals and providing a convenient prescription experience for…View ↗
Did Revenues Turn Into Profits?
No. It lost $51.7M in FY2022.
10-K for FY2022, filed Mar 20, 2023
−$59MView ↗
10-K for FY2022, filed Mar 20, 2023
−$51.7MView ↗
10-K for FY2022, filed Mar 20, 2023
−$38.6MView ↗
How Were They Changing?
- Net income
-
Sources
10-Q for Q2 FY2023, filed Aug 14, 2023
−$23.9MView ↗
- ▲ +97% (Loss)
- vs −$12.1M in Q2 FY2022
-
Feb 13, 2024
Irish court orders RVL Pharmaceuticals plc wound up
A liquidator was appointed; the order will lead to the company's winding up and eventual dissolution.
Sources
8-K, filed Feb 13, 2024
On February 12, 2024, the High Court of Ireland made a winding up order in respect of RVL Pharmaceuticals plc (the “Company”) pursuant to…View ↗
-
Nov 27, 2023
NewCo took ownership of RVL Pharmaceuticals, Inc.
Athyrium funds received 97.5% of NewCo equity; RVL plc retained substantially no assets or operations after the restructuring.
Sources
8-K, filed Nov 27, 2023
In accordance with the Amended Plan, on November 22, 2023 (the “Effective Date”) funds managed by Athyrium Capital Management, LP…View ↗
Shift from a broad portfolio to Upneeq
The older report described promoted neurology and women's health products alongside non-promoted medicines; the latest centers commercial activity on Upneeq after selling that portfolio and its manufacturing facility, while retaining arbaclofen ER.
10-K for FY2019, filed Mar 19, 2020 10-K for FY2022, filed Mar 20, 2023We are a fully integrated biopharmaceutical company focused on the development and commercialization of specialty products that target…View ↗
Our core competencies span drug development, manufacturing and commercialization. Our team of sales representatives support the ongoing…View ↗
December 31, 2019, we sold a portfolio consisting of approximately 30 non-promoted products. The cash flow from these non-promoted products…View ↗
We are a specialty pharmaceutical company focused on the development and commercialization of products that target markets with underserved…View ↗
On August 27, 2021, we announced the closing of the divestiture of our portfolio of branded and non-promoted products and our Marietta…View ↗
With the divestiture of the Legacy Business, our commercial operations are conducted by our wholly-owned subsidiary, RVL Pharmaceuticals…View ↗
Upneeq moved from pipeline to sales
The older report described the ocular treatment as a late-stage candidate awaiting regulatory action; the latest describes it as approved and marketed through the pharmacy, direct sales to practices, and telemedicine providers.
10-K for FY2019, filed Mar 19, 2020 10-K for FY2022, filed Mar 20, 2023We are a fully integrated biopharmaceutical company focused on the development and commercialization of specialty products that target…View ↗
We are a specialty pharmaceutical company focused on the development and commercialization of products that target markets with underserved…View ↗
Broaden Distribution Channels for Upneeq. Following FDA approval in July 2020, we launched Upneeq in eye care specialties and made the…View ↗
In 2022 we started supplying Upneeq to certain telemedicine providers with established channels to diagnose patients online and prescribe…View ↗
Loading...
